Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TRAIL/CD253/TNFSF10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TRAIL/CD253/TNFSF10 (Soluble ECD, Homotrimer-designed) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View TRAIL Products |
| Gene Delivery | TRAIL/CD253/TNFSF10 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and expression validation. |
View TRAIL Products |
| Benchmark Ab | Anti-TRAIL Recombinant Reference Antibody Recombinant positive control matching clinical benchmark sequence. |
View TRAIL Products |
| Validator | TRAIL/CD253/TNFSF10 siRNA Set For target knockdown verification in functional assays. |
View TRAIL Products |
| Related Target A | DR5 / TRAIL-R2 Primary death receptor mediating TRAIL-induced apoptosis in cancer cells. |
View DR5 Products |
| Related Target B | DR4 / TRAIL-R1 Alternative death receptor triggering caspase cascade activation. |
View DR4 Products |
| Related Target C | DcR1 / TRAIL-R3 Decoy receptor lacking intracellular death domain; critical for off-target selectivity screening. |
View DcR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Decoy Receptor Off-Target Screening | Full panel of human DR4, DR5, DcR1, and DcR2 recombinant proteins available with high purity (>95%) for SPR/BLI selectivity profiling. |
| Trimerization-Dependent Activity | Soluble TRAIL antigens designed for native-like homotrimeric assembly, verified by size exclusion chromatography (SEC). |
| Lack of Reference Standards | Clinical Benchmark Antibodies included to validate assay sensitivity and baseline apoptosis induction. |
| Assay Noise & Non-Specific Toxicity | Strictly endotoxin-controlled formulations (<1.0 EU/μg) to prevent TLR-mediated background activation in immune cell assays. |
Live TRAIL/CD253/TNFSF10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development of TRAIL (TNFSF10) is undergoing a major renaissance. Early-generation recombinant TRAIL (e.g., dulanermin) and first-generation agonistic antibodies targeting DR4 or DR5 suffered from poor clinical efficacy due to short half-lives and weak receptor clustering. The modern R&D landscape has shifted away from simple monovalent targeting toward multivalent agonists, bispecific fusion proteins, and tumor-anchored TRAIL variants designed to maximize death receptor clustering while sparing normal hepatocytes.
As next-generation molecules enter clinical trials, the focus has pivoted to engineering tumor-restricted activation (e.g., bispecifics targeting tumor-associated antigens like FAP or EGFR fused to TRAIL) and developing highly stable, hexavalent TRAIL-receptor agonists. Overcoming resistance mechanisms, such as caspase-8 downregulation or FLIP overexpression, remains a key driver for combination therapy trials.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Hexavalent Agonists | AbbVie, Apogenix | Solid Tumors, Glioblastoma | Receptor clustering assays requiring highly pure, monomeric vs. oligomeric DR4/DR5 target proteins. |
| Bispecific Fusion Proteins | Roche, Genentech | Colorectal Cancer, NSCLC | Dual-binding affinity validation (e.g., TAA + DR5) using sequence-verified target antigens. |
| Circularly Permuted TRAIL (CPT) | Beijing Sunbio Biotech | Multiple Myeloma, Lymphoma | In vitro apoptosis assays requiring high-purity, endotoxin-controlled soluble TRAIL variants. |
| Cell & Gene Therapy | Academic Institutions, Biotech | Advanced Solid Tumors | Lentivirus-based ORF expression vectors for stable target validation in effector/target cell co-cultures. |